Our goal at MTRC is to inform the decision-making of our clients and to support their market access activities. Below is a snapshot of our planned activities for the next two weeks. This can help our existing and prospective clients understand the potential scope of our support better. From the week of April 6th, we plan to work on 15 projects. Review the complete list of planned activities in this post.

In late March 2026, Norway’s “New Methods” framework announced a revised process for managing medical technologies (i.e., medical devices, in-vitro diagnostics, procedures), effective May 1, 2026. The update introduces new entry pathways, application process, prioritization criteria, and procedural changes such as early assessment and implementation meetings. Medical device companies are invited to a digital information session on April 17, 2026, with registration required by April 14, 2026.

The French National Authority for Health (HAS) released new recommendations on the registration of medical devices and medical aids in the List of Reimbursable Products and Services (LPPR) following the March 2026 meetings of the National Commission for the Evaluation of Medical Devices and Health Technologies (CNEDiMTS). A favorable opinion was issued on the add-on reimbursement for three new devices in the gastrointestinal endoscopy, men’s health, and orthopedics fields.

On March 26, 2026, NHS England published the final version of the 2026/27 NHS Payment Scheme, effective from April 1, 2026. While the overall payment model remains largely unchanged, several targeted updates have been introduced. These include new blended payments for urgent and emergency care, radiotherapy, and genomic testing, as well as two new Best Practice Tariffs (BPTs) to incentivize day case procedures and support 10 Year Health Plan referral-to-treatment (RTT) priorities.

The Danish Health Data Authority quarterly updates the Health Care Classification System (SKS). The latest version was published in mid-March 2026 to come into force on April 1, 2026. Among other changes, 32 new procedure codes concerning extracorporeal treatments, interventional radiology, ICU/OR, ophthalmology, pulmonary and airways, surgical procedures, and some other fields were introduced.

In March 2026, the Dutch Healthcare Authority (NZa) published regulations on the budgetary funding for emergency care. The final financial result is determined by the revenue from the provisional budget (set in advance) and the final budget (determined after the end of the year). A new supplementary payment with a fixed, provider-specific tariff will be introduced for the billing and calculation of budgets of ER departments. The regulations enter into force on July 1, 2026.

In March 2026, the SwissDRG, the entity managing the DRG system in Switzerland, announced that it would be accepting applications for changes from June 1, 2026, until July 13, 2026. The results of the DRG applications made in 2026 will be reflected in the 2028 version of the SwissDRG.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Publications Digest. In a recent publication, Cresswell et al. reviewed global regulatory and HTA policies on real-world evidence use.

In February 2026, the French Ministry of Health, Family, Autonomy, and People with Disabilities announced three new experiments under Article 51 of the Social Security Financing Act. They relate to nephrology and neuro-orthopedics, and to the provision of care to discharged, dependent, elderly individuals experiencing loss of autonomy or chronic illness.

As of March 2026, the Scottish Health Technologies Group is working on health technology assessments in several areas, including diagnostic imaging, e-health, endoscopy, ENT, in-vitro diagnostics, and radiotherapy.

In March 2026, the Belgian National Institute for Health and Disability Insurance (INAMI/RIZIV) updated the List of implants and invasive medical devices, effective April 1, 2026. One new material code was introduced for radiofrequency ablation of benign thyroid nodules. Nominative lists of brands were updated as well, with new devices added in the cardiovascular, neurovascular, orthopedics, and some other fields.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its EU HTA Publications Digest. In a recent publication, Julian et al. developed a stakeholder-centric framework of key performance indicators to support implementation of the EU HTA Regulation across Europe using a modified Delphi approach.